24.8 C
Vientiane
Thursday, August 21, 2025
spot_img
Home Blog Page 32

U Power Announces Strategic Partnership with SAIC-Hongyan and UNEX EV to Deploy Battery-Swapping Compatible Heavy Trucks in Thailand and Beyond

Addressing the Demand for Green and Sustainable Transportation Solutions in the Logistics Industry

SHANGHAI, Aug. 18, 2025 /PRNewswire/ — U Power Limited (Nasdaq: UCAR) (the “Company” or “U Power”), a provider of AI-powered solutions for next-generation energy grids and intelligent transportation systems, building on its proprietary UOTTATM electric vehicle (EV) battery-swapping technology, today announced that it has signed a Memorandum of Understanding (“MOU”) with SAIC HONGYAN Automotive Co., Ltd (“SAIC Hongyan”), a company focused on the development, manufacture, sales and services of heavy trucks, and UNEX EV B.V. (“UNEX EV”), a new energy and technology company, to cooperate on the deployment of battery-swapping compatible electric heavy trucks initially in Thailand and explore similar expansion opportunities in additional markets.

The three parties will collaborate to deploy 3,000 electric heavy-duty tractors for long-haul transportation and 1,200 electric heavy-duty port-specific short-distance trucks in Thailand. This initiative aims to promote the adoption of green and sustainable commercial heavy trucks in Thailand. In addition, all parties have agreed to explore the expansion of this partnership into additional markets, including the broader Southeast Asia, Latin America, Europe, Hong Kong SAR and Macau SAR.

Pursuant to the MOU, U Power will lead the development and manufacture of compatible battery-swapping stations as well as provide related operational services. UNEX EV will be responsible for the adaption of SAIC Hongyan heavy trucks into battery swapping-enabled vehicles, developing of compatible battery modules, as well as promoting the sales of the heavy trucks in the Thailand market. SAIC Hongyan will supply heavy truck prototypes and provide the necessary technical support to ensure full compatibility between these adapted truck models and U Power’s smart battery-swapping stations.

Together, the three parties aim to address a rising need for green and renewable logistic solutions in Thailand, with a focus on servicing major highway transportation enterprises and container port operators that require terminal tractors.

Pitak Pruittisarikorn, CEO of UNEX EV, commented, “We are excited to deepen our collaboration with U Power and SAIC Hongyan to bring cutting-edge, battery-swapping compatible heavy-duty EV solutions to Thailand’s commercial transportation sector. This strategic partnership reflects our shared commitment to accelerating the global shift toward zero-emission logistics. By combining our deep local market insight and a global ecosystem of clean mobility technologies, we aim to pave the way for a scalable and sustainable heavy truck electrification model, not just for Thailand, but also for emerging logistics hubs across Southeast Asia and beyond.”

“Partnering with U Power and UNEX EV allows SAIC Hongyan to bring our robust heavy truck platforms into a new era of electrification and intelligent mobility,” said Ms. Xiong, General Manager of Overseas Sales at SAIC Hongyan. “Through compatibility with battery-swapping technology, we aim to deliver operational flexibility and enhanced efficiency to fleet operators in Thailand’s long-haul and port logistics industries. We look forward to jointly creating a benchmark for green, intelligent heavy-duty transport that can be replicated across more regions globally.”

Johnny Lee, CEO and Chairman of U Power commented, “We are pleased to expand our strategic partnership and scope of collaboration with SAIC and UNEX EV, two of U Power’s key allies in the development and manufacturing of battery-swapping compatible vehicles. Together, we identified a growing demand for sustainable transportation solutions within Thailand’s logistic industry. We believe our combined expertise positions us well to capitalize on this opportunity, enhance our presence in the Thailand market and further drive growth as we continue to build a battery-swapping ecosystem here. In July, we launched Southeast Asia’s first operational smart battery-swapping station on Phuket Island, Thailand. Earlier, in April 2025, in collaboration with UNEX EV and SAIC CP-MG, we successfully delivered the first batch of swappable electric vehicles for taxi and ride-hailing services on the island. We look forward to extending our collaboration in more regional markets.”

About SAIC HONGYAN Automotive Co., Ltd

SAIC Hongyan is the only heavy truck enterprise under SAIC Group (SSE: 600104). SAIC Hongyan is headquartered in Chongqing City, China, with more than 5,000 employees and an annual output of 120,000 vehicles. SAIC Hongyan has 300+ first-class heavy truck dealers, 1,000+ service providers, and global supply chain procurement of parts and components. SAIC Hongyan’s heavy truck series products are exported to more than 40 countries and regions in the Middle East, Africa, Central America and Southeast Asia.

About UNEX EV B.V.

Founded in the Netherlands, UNEX EV is a global pioneer in electric mobility innovation, dedicated to revolutionizing how industries move, specializing in designing and deploying a comprehensive ecosystem of battery-swapping electric vehicles—including passenger cars, commercial vehicles, two-wheelers, drones, and barges—paired with cutting-edge energy infrastructure and AI-driven fleet management systems. With regional hubs in Portugal, Peru, Mexico, Thailand, and China, UNEX EV’s solutions are transforming mobility challenges into opportunities.

About U Power Limited

U Power is a provider of comprehensive AI-integrated energy solutions that connect electric vehicles (EVs) with advanced energy infrastructure, optimizing both mobility and grid performance. Originally a distributor of various battery-swapping station models built on its proprietary modular battery-swapping technology UOTTA™, U Power has evolved into a provider of AI-integrated solutions for energy grids and transportation systems.

Through investments in next-generation technologies, U Power is building intelligent ecosystems that integrate resilient AI driven solutions able to transform EVs into dynamic energy assets. By incorporating AI algorithms, U Power’s comprehensive solutions for smart energy grids are designed to support autonomous EV driving, optimize energy replenishment efficiency, and seamlessly connect EV assets with advanced AI-powered transportation systems, enabling peak and off-peak energy load balancing.

For more information, please visit the Company’s website: https://www.upower-limited.com/.

Safe Harbor Statements

This press release contains “forward-looking statements”. Forward-looking statements reflect our current view about future events. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “could,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “propose,” “potential,” “continue” or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results, and encourages investors to review other factors that may affect its future results in the Company’s registration statements and other filings with the U.S. Securities and Exchange Commission. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. References and links (including QR codes) to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.

Contact 
U Power Limited 
Investor Relations Department
ir@upincar.com

The Equity Group
Lena Cati, Senior Vice President
212-836-9611 / lcati@theequitygroup.com 

Alice Zhang, Associate
212-836-9610 / azhang@theequitygroup.com  

LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company

BEIJING, Aug. 18, 2025 /PRNewswire/ — LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (“LakeShore Biopharma” or the “Company”), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its board of directors (the “Board”) has received a preliminary non-binding proposal letter (the “Proposal Letter”), dated August 18, 2025, from Oceanpine Investment Fund II LP and Oceanpine Capital Inc. (collectively, “Oceanpine Capital”) to acquire all of the outstanding ordinary shares, par value US$0.0002 per share, of the Company (the “Ordinary Shares”) that are not currently owned by Oceanpine Capital in an all-cash transaction for US$0.86 per Ordinary Share (the “Proposed Transaction”). A copy of the Proposal Letter is attached hereto as Exhibit A.

The proposed purchase price represents a premium of 10.3% to the Company’s last closing price on August 15, 2025, the last trading day prior to the date of the Proposal Letter, and a premium of 11.4% to the average closing price of the Ordinary Shares during the last 15 trading days prior to the date of the Proposal Letter. According to the Proposal Letter, Oceanpine Capital intends to fund the Proposed Transaction with rollover equity and available cash on hand, and the Proposed Transaction will not be subject to a financing condition. Oceanpine Capital has engaged White & Case LLP as its international legal advisor for the Proposed Transaction.

The Board has just received the Proposal Letter and will carefully review and evaluate the proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders.

The Company cautions its shareholders and others considering trading in its securities that the Board has just received the Proposal Letter and has not made any decisions with respect to the Company’s response to the proposal. There can be no assurance that any definitive offer will be made, that any agreement will be executed, or that the Proposed Transaction or any other transaction will be approved or consummated. The Company does not undertake any obligation to provide any updates with respect to this or any other transaction, except as required under applicable law.

About LakeShore Biopharma

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA® immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Hepatitis B, Influenza, and other virus infections. The Company operates in China, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the biopharmaceutical industry. For more information, please visit please visit https://investors.lakeshorebio.com/.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical or current fact included in this press release are forward-looking statements, including but not limited to statements regarding the Board’s evaluation of the Proposal Letter and the Proposed Transaction. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “potential,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “goal,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements are based on various assumptions, whether identified in this press release, and on the current expectations of LakeShore Biopharma’s management and are not predictions of actual performance.

LakeShore Biopharma cannot assure you the forward-looking statements in this press release will be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including those included under the heading “Risk Factors” in the Company’s Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, and other risks described in documents subsequently filed by the Company from time to time with the SEC. There may be additional risks that LakeShore Biopharma does not presently know or that LakeShore Biopharma currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. The forward-looking statements in this press release represent the views of LakeShore Biopharma as of the date of this press release. Subsequent events and developments may cause those views to change. However, while LakeShore Biopharma may update these forward-looking statements in the future, there is no current intention to do so, except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing the views of LakeShore Biopharma as of any date subsequent to the date of this press release. Except as may be required by law, LakeShore Biopharma does not undertake any duty to update these forward-looking statements.

Exhibit A

Preliminary Non-Binding Proposal

August 18, 2025

The Board of Directors (the “Board“)
LakeShore Biopharma Co., Ltd
Building No. 2, 38 Yongda Road
Daxing Biomedical Industry Park
Daxing District, Beijing, 102629
People’s Republic of China

Dear members of the Board:

We, Oceanpine Investment Fund II LP and Oceanpine Capital Inc. ( collectively, “Oceanpine Capital”), are pleased to submit this preliminary non-binding proposal (the “Proposal”) to acquire all outstanding ordinary shares of a par value of US$0.0002 each (the “Ordinary Shares”) of LakeShore Biopharma Co., Ltd (the “Company”) that are not currently owned by us, in an all-cash transaction for US$0.86 per Ordinary Share (the “Proposed Transaction”).

Our Proposal represents a premium of 10.3% to the last closing price of the Ordinary Share on August 15, 2025, the last trading day prior to the date hereof, and a premium of 11.4% to the average closing price of the Ordinary Shares during the last 15 trading days prior to the date hereof. We believe that our Proposal represents an attractive opportunity for the Company’s shareholders to receive compelling value as compared with the current and recent trading prices of the Ordinary Shares.

We intend to fund the Proposed Transaction with rollover equity and available cash on hand. Accordingly, our Proposal would not be subject to any uncertainty or delay with respect to any debt financing, and the Proposed Transaction will not be subject to a financing condition.

We do not anticipate any substantive issues with respect to regulatory approvals, nor do we believe that any regulatory approval will impede or delay our ability to quickly and efficiently consummate the Proposed Transaction.

We have engaged White & Case LLP as our international legal advisor for the Proposed Transaction. We are confident that we can complete customary due diligence in a timely manner, in parallel with discussions on the definitive agreements.

We recognize that the Board will likely need to evaluate our Proposal independently before the Company can make any determinations. None of the Company’s directors who are affiliated with us will participate in the consideration of our Proposal by the Company.

While we are fully prepared to work collaboratively with the Board to pursue the Proposed Transaction in a timely manner, we are open to exploring potential alternative structures of the Proposed Transaction to expedite the process of delivering value to the Company’s shareholders.

Following completion of the Proposed Transaction, we currently intend for the Company’s business to continue operating in a manner that is generally consistent with its current operations.

This letter constitutes only a preliminary indication of our interest and does not constitute any binding commitment with respect to the transactions proposed in this letter or any other transaction. No agreement, arrangement or understanding between us and the Company relating to any transaction will be created until such time as definitive documentation has been executed and delivered by us and the Company and all other appropriate parties.

About Oceanpine Capital

Founded in 2018, Oceanpine Capital is a professional investment management firm dedicated to long-term value investing. With a mission to drive technological innovation, it focuses on cutting-edge sectors such as advanced technology, green technology and life sciences, with assets under management exceeding RMB25 billion (approximately USD3.5 billion). As the “Guardian of Entrepreneurship”, Oceanpine Capital brings together a seasoned team of accomplished entrepreneurs, renowned investors, seasoned investment bankers, and senior executives from leading corporations. Oceanpine Capital provides its portfolio companies with full-cycle support, ranging from strategic planning and resource integration to operational optimization and global expansion, empowering them to achieve leapfrog growth at critical stages.

Should you have any questions regarding this Proposal, please do not hesitate to contact us. We look forward to hearing from you.

Sincerely,

Oceanpine Investment Fund II LP

By:

/s/ Dave Liguang Chenn

Name:

Dave Liguang Chenn

Title:

Director

Oceanpine Capital Inc.

By:

/s/ Yang Jiayu

Name:

Yang Jiayu

Title:

Director

 

NAVEE ST3 Pro Electric Scooter Wins Prestigious 2025 Innovation Award for Best Electric Scooter

SHENZHEN, China, Aug. 18, 2025 /PRNewswire/ — NAVEE’s flagship ST3 Pro electric scooter was named “Best Electric Scooter” at the Active Lifestyle Innovation Awards 2025 in early August, a respected international honor celebrating breakthrough consumer technology. The award is organized by Future, the global media group behind top tech publications such as Tom’s Guide, TechRadar, and Android Central.

The ST3 Pro, first released at CES 2025, is engineered for smooth, efficient, and safe commuting. Its Advanced Damping Arm™ Suspension Technology features a dual-sided suspension system with four polymer damping arms, dramatically reducing road vibrations and providing the most comfortable riding experience over cobblestones, uneven pavements, and urban speed bumps.

Powered by a 600W rated motor (up to 1350W peak) and a 48V 12.75Ah battery, the scooter offers a maximum range of 46.6 miles (75 km) and a top speed of 25 mph (40 km/h). Its 28% climbing ability ensures confident performance on steep inclines, while the foldable design and intuitive controls make it ideal for daily use in busy city environments. Additional safety features include front drum and rear disc brakes with EABS, high-visibility lighting, and a durable frame built to withstand varied road conditions.

NAVEE ST3 Pro Electric Scooter
NAVEE ST3 Pro Electric Scooter

This blend of performance, comfort, and safety impressed the Innovation Awards judges, who evaluate entries on design, performance, sustainability, and user experience. Winning this award highlights NAVEE’s commitment to delivering high-quality, cutting-edge urban mobility solutions, and further establishes the ST3 Pro as a top choice for riders seeking premium performance and reliability.

The ST3 Pro is available through NAVEE’s official sales channels, including the Official Store and Amazon Store. It is also sold in 17 independent physical stores across cities such as New York, California, and New Jersey, as well as at major retailers like Best Buy, Target, and Walmart.

Beyond electric scooters, NAVEE is an emerging brand reshaping short-distance transportation. Known for blending innovation with lifestyle design, NAVEE is also exploring specialized mobility products. The company just debuted the Birdie 3 Series golf push cart — a 4+1-wheel configuration model equipped with 11-inch all-terrain rear wheels, tailored for stability and ease of maneuverability on golf courses.

About NAVEE

NAVEE is a leading brand in the electric mobility sector, offering a wide range of products that combine cutting-edge technology, high-quality design, and sustainability. For more information, please visit https://naveetech.us/

Dingdong to Report Second Quarter 2025 Financial Results on August 21, 2025

SHANGHAI, Aug. 18, 2025 /PRNewswire/ — Dingdong (Cayman) Limited (“Dingdong” or the “Company”) (NYSE: DDL), a leading fresh grocery e-commerce company in China, with advanced supply chain capabilities, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2025, before U.S. markets open on August 21, 2025.

The Company will hold an earnings conference call at 8:00 A.M. Eastern Time on Thursday, August 21, 2025 (8:00 P.M. Beijing Time on the same day) to discuss its financial results. Management’s prepared remarks and the question-and-answer session will be conducted in English and Mandarin. Dial-in details for the earnings conference call are as follows:

International:

1-412-317-6061

United States Toll Free:

1-888-317-6003

Mainland China Toll Free:

+86-4001-206115

Hong Kong Toll Free:

800-963976

Conference ID:

0358096

The replay will be accessible through August 28, 2025 by dialing the following numbers:

International:

1-412-317-0088

United States:

1-877-344-7529

Access Code:

5040747

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https://ir.100.me.

About Dingdong (Cayman) Limited

Dingdong is the leading fresh grocery e-commerce company in mainland China, with sustainable long-term growth. The Company directly provides users and households with fresh groceries, prepared food, and other food products through delivering a convenient and excellent shopping experience supported by an extensive self-operated frontline fulfillment grid. Leveraging its deep insights into consumers’ evolving needs and its strong food innovation capabilities, Dingdong has successfully launched a series of private label products spanning a variety of food categories. Many of Dingdong’s private label products are produced at its own production plants, allowing it to more efficiently produce and offer safe and high-quality food products. Dingdong aims to be the first choice for fresh and food shopping.

For more information, please visit: https://ir.100.me.

 

XtalPi Holdings Limited to Announce 2025 Interim Results on August 27, 2025

CAMBRIDGE, Mass., Aug. 18, 2025 /PRNewswire/ — XtalPi Holdings Limited (“XtalPi”, or the “Company”) (HKEX: 2228), a leading global technology company in integrating artificial intelligence (AI) and robotics for drug and materials discovery, announced that it will report its interim results for the six months ended June 30, 2025 on Wednesday, August 27, 2025, after the Hong Kong market closes.

The Company will hold a conference call in Chinese with English simultaneous interpretation at 7:00 PM Hong Kong/Beijing Time on August 27, 2025 (7:00 AM U.S. Eastern Time on the same day). Details for the conference call are as follows:

For Chinese original audio channel:

Online Registration Link: https://s.comein.cn/five6xyc

Alternatively, participants may access the conference call by dialing the following numbers:

Mainland China:

+86-4001510269

International:

+86-1021377168

Hong Kong, China:

+852-51089680

Taiwan, China:

+886-277083288

United States:

+1-2087016888

Password:

197788

The replay of the conference call will be available on the Company’s investor relations website at https://ir.xtalpi.com/en/investor-relations.

For English simultaneous interpretation channel:

Online Registration Link: https://s.comein.cn/s288yddg

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

Investor Relations Contact:

In China:

XtalPi Holdings Limited
Investor Relations
Email: ir@xtalpi.com

Piacente Financial Communications
Tel: +86-10-6508-0677
Email: XtalPi@thepiacentegroup.com

In the United States:

Piacente Financial Communications
Brandi Piacente
Tel: +1-212-481-2050
Email: XtalPi@thepiacentegroup.com

AI Agent Drives New Growth︱SY Holdings Reports 2025 Interim Results: Net Profit Up 23%; E-commerce Business Volume Surges Eightfold

SHENZHEN, CHINA – EQS Newswire – 18 August 2025 – SY Holdings Group Limited (“SY Holdings” or the “Company”; Stock Code: 6069.HK), a digital intelligence technology company specialising in “AI + industrial supply chain” solutions, announced its interim results for the six months ended 30 June 2025.

According to the announcement, SY Holdings has been deeply implementing its “AI+” strategy, continuously advancing the commercialisation of AI Agent applications to support the growth of SMEs. As of 30 June 2025, the Company recorded a net profit of over RMB 2.03 billion, marking a year-on-year increase of 23%.

Leveraging AI Agent and other advanced technologies, based on comprehensive integration of industry ecosystems and data, SY Holdings fully exploits the benefits of its distinctive risk control model characterised by a “transaction-focused, asset-light” approach. The Company helps SMEs in the supply chain to “secure orders and access funding,” while offering efficient, cost-effective, and high-quality financing facilitation services.

For the six months ended 30 June 2025, the Company reported revenue and income from core business activities of approximately RMB 0.4 billion. The platform facilitated cumulative funding turnover of more than RMB 278.0 billion, a rise of over 29% compared to the same period last year, and served more than 19,100 customers in total, an increase of over 14% year-on-year. SMEs customers accounted for over 97% of the total customer base, with first-time borrowers making up more than 30%. The Company’s platform has helped customers reduce financing costs by at least 30%.

SY Holdings continued to develop its platform-based strategy, with its self-developed AI Agent—”SY Cloud Platform”—as the central hub to establish an efficient and intelligent matching mechanism between the industry and funding partners, supporting the rapid growth of its “asset-light” operating model.

As of 30 June 2025, the platform had established strategic partnerships with over 10 Fortune Global 500 companies and developed relationships with more than 180 funding partners, representing an increase of 31% year-on-year, positioning itself as a key partner for financial institutions in promoting inclusive finance. Based on this foundation, platform-based facilitation business accounted for approximately 88% of the total business volume, up 28 percentage points from the same period last year.

Platform technology service revenue reached approximately RMB 0.21 billion, showing a year-on-year increase of 37% and constituting 52% of total revenue—outpacing its growth target six months early and poised to significantly boost future earnings.

2025 is seen as the inaugural year for widespread commercial use of AI Agents. SY Cloud Platform has thoroughly integrated with popular open-source large language models like DeepSeek, Qwen, and Doubao, leading the way in offering diverse value-add services to its ecosystem partners.

For example, in the infrastructure sector, the platform can automatically gather tender and procurement information through multiple channels, perform data cleaning and data organization, and convert it into a standard format that is easy to analyse, covering key details such as project type, scale, budget, and technical requirements. By leveraging information on suppliers’ business scope, production capacity, qualification level, and historical bidding records, the platform delivers highly relevant tender opportunities directly to suitable suppliers.

Furthermore, the platform offers suppliers assistance with bidding document preparation, analysis of the competitive landscape, and pricing strategy advice, enabling them to enhance both bidding efficiency and success rates. By 30 June 2025, SY Holdings reported its initial revenue from AI-driven order acquisition, with income from AI “order-matching” services surpassing RMB 400,000.

In an era of rapid advances in AI technology, SY Holdings has continued to increase its investment in research and development. As of 30 June 2025, the Company’s cumulative R&D investment was close to RMB 270 million, with R&D personnel accounting for approximately 30% of the total staff. The Company holds 88 national invention patents and computer software copyrights, covering multiple fields including AI, big data, and cloud computing.

Building on this foundation, SY Holdings has developed and deployed a range of innovative applications, such as intelligent document sorting, intelligent contract review, and AI-powered customer service, collaborating closely with ecosystem partners to achieve cost reduction and efficiency improvements. During the reporting period, the average asset service volume per capital increased by approximately 27%, while our customers’ sales volume grew by over 60% year-on-year.

Demonstrating strong confidence in its long-term value and high regard for its future growth prospects, SY Holdings has announced a special dividend of RMB 600 million for 2025 and committed to maintaining a dividend payout ratio of no less than 90% for the financial years 2025 and 2026, thus continuing to share the company’s growth outcomes with its shareholders. Based on this pledge, the total dividend payout for 2025 will be approximately RMB 950 million. As of the closing price on the date of this results announcement, the dividend yield is estimated at around 8%.

SY Holdings has received unanimous backing from prominent institutions—including CICC; Tianfeng Securities, CSC(China Securities); SDIC Securities; Soochow Securities; Sinolink Securities; GF Securities; Guolian Securities; Phillip Securities; and Zheshang Securities—each assigning the Company a ‘Buy’ or ‘Outperform’ rating, with the highest target price of HK$21.65.

Expanding into New Sectors, Building New Growth Engines

While deepening its presence in key national industries such as infrastructure, healthcare, pharmaceuticals, and commodities, SY Holdings is also actively expanding into strategic emerging sectors including e-commerce and robotics. These emerging sectors together represent a potential market size of more than RMB 70 trillion and a customer base of over 26,000 thousand enterprises.

In the e-commerce sector, SY Holdings has expanded its coverage to six leading platforms, including Douyin, SHEIN, Shopee, Kuaishou, WeChat Channels, Poizon. As of 30 June 2025, the company’s cumulative e-commerce financing facilitation volume surpassed RMB 2.8 billion, reflecting an almost eightfold increase year-on-year.

Recently, SY Holdings completed system integration with a leading global fashion e-commerce platform and successfully embedded end-to-end online services within the platform. Through this integration, e-commerce merchants can utilise their “shipped but pending settlement orders” to create a virtuous cycle of “sales – early payment collection – repurchase – further sales,” thereby further expanding the growth potential of SY Holdings’ e-commerce sector business.

In the robotics sector, SY Holdings has formed a strategic partnership with Standard Robots (Wuxi) Co., Ltd., a global leader in industrial intelligent robotics, through investment, successfully launching its first innovative supply chain services transaction in the robotics industry. This collaboration has laid the groundwork for SY Holdings to expand into a new business segment, while the Company actively explores partnership models with enterprises engaged in industrial, service, and specialised robotics to accelerate its presence in China’s robotics market, which is valued at over RMB 190 billion.

In terms of strategic investment, SY Holdings has brought in XtalPi Inc. (Stock Code: 2228.HK)—known as the “first AI-for-Science stock”—and Be Friends Holding Ltd. (Stock Code: 1450.HK), a leading cross-platform live-streaming e-commerce company, as strategic investors. This move aims to bolster the company’s AI R&D capabilities, develop vertical-industry AI Agents, and rapidly penetrate the live-streaming e-commerce space.

In terms of computing power reserves, SY Holdings has secured support from the Wuxi Economic Development Zone and officially connected to the Xuelang Computing Center, NVIDIA AI Computing Center, and Sugon Advanced Computing Center, all operated by Wuxi Digital Whale Technology Co., Ltd. (“Digital Whale”). Digital Whale currently has more than 60 H800 servers in reserve, providing intelligent computing capacity exceeding 1,000P.

Leveraging these resources, SY Holdings will enable ecosystem partners to access sufficient intelligent computing capacity to meet advanced computing requirements across multiple scenarios, including model training and application deployment. The Company will continue to focus on the R&D and application of AI Agents, with operational efficiency expected to improve further in 2025. Average service volume per capita is projected to expand significantly, providing strong support for the Group’s profit growth.

Embracing Web 3.0 to Accelerate Expansion of International Operations

Currently, the international order is experiencing significant and complex changes, with the ongoing restructuring of global supply chains. Issues such as notable exchange rate volatility, low payment efficiency, and difficult market access have become key obstacles limiting the globalization of SMEs.

Recently, SY Holdings set up its international headquarters in Singapore to further grow its presence in overseas markets and to explore innovative uses for Web 3.0 and stablecoins.

In international business development, SY Holdings has established a strategic partnership with Xinbada (Guangzhou) Technology Co., Ltd., a leading supplier to SHEIN, through investment. The company will support the development of flexible, intelligent factories in overseas markets such as Turkey, Southeast Asia, and Morocco. Additionally, it will utilise the supplier’s role within the industrial ecosystem serving cross-border e-commerce platforms including SHEIN, Temu, Cider, and PatPat to speed up the global growth of China’s apparel manufacturing hubs and cross-border e-commerce platforms.

Furthermore, SY Holdings has been continuously expanding its business layout in Southeast Asia and has completed its first international financing transaction. Using its international market resources and platform connectivity, the Company will also support key pharmaceutical enterprises in processing and fulfilling export orders for herbal products.

It is worth noting that stablecoins, as an emerging payment and settlement instrument pegged to fiat currencies, leverage blockchain’s peer-to-peer transfer capabilities to enable instant “payment-equals-settlement” clearing, while reducing transaction costs to as low as 0.1%. SY Holdings plans to explore innovative applications of stablecoins in facilitating international supply chain finance services, aiming to improve capital turnover, lower cross-border payment costs, and reduce foreign exchange volatility risks. In doing so, the Company seeks to provide an optimal customer experience characterised by speed, efficiency, quality, and cost-effectiveness, and to act as a bridge for SMEs in the Asia-Pacific region as they expand globally.

Looking ahead, as AI and Web 3.0 become increasingly integrated, the technological foundations of the digital world are undergoing a profound transformation. SY Holdings will continue to leverage technology to connect industries and ecosystems, working together with SMEs to reshape global supply chains.

Hashtag: #SYHoldings

The issuer is solely responsible for the content of this announcement.

KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS

  • Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion
  • Research and development expenses was approximately RMB611.5 million
  • Loss for the period was RMB145.2 million; adjusted loss for the period[1] was RMB69.4 million
  • Cash and cash equivalents[2] amounted to approximately RMB4527.8 million, reflecting ample cash reserves

Note1: Calculated by deducting equity-settled share-based payment from loss for the year.

Note2: Comprises cash and cash equivalents, restricted deposits, financial assets measured at fair value through profit or loss, financial assets measured at amortized cost and financial assets measured at fair value through other comprehensive income.

 

CHENGDU, China, Aug. 18, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Pharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company“, Stock Code: 6990.HK) announced its unaudited interim results for the six months ended 30 June 2025 (the “Reporting Period“).

In the first half of 2025, China’s biopharmaceutical industry reached an inflection point for high-quality growth, driven by accelerated innovation in drug research and development, the rollout of favorable policies, increasing momentum in industry collaboration and mergers and acquisitions. Kelun-Biotech capitalized on these opportunities by its proprietary technology platforms, innovation-led R&D, and a well-established commercialization infrastructure. These elements have worked together to enable the Company to establish a fully integrated model covering R&D, clinical development, manufacturing, and commercialization.

Focusing on addressing significant unmet medical needs in both oncology (such as breast cancer (BC), non-small cell lung cancer (NSCLC), and gastrointestinal (GI) cancers including gastric cancer (GC) and colorectal cancer (CRC)) and non-oncology diseases, the Company has developed a rich and diverse pipeline of over 30 candidates. More than 10 of these candidates have already entered clinical stage. At the same time, the Company continues to invest in next-generation conjugation technologies and a diversified portfolio of assets, aiming to deliver innovative therapies for patients worldwide and contribute to the improvement of global healthcare.

ADC & novel DC assets breakthroughs are redefining the treatment landscape.

sac-TMT (sacituzumab tirumotecan, SKB264/MK-2870,佳泰萊®)

The first TROP2 ADC drug approved for marketing in LC globally.

TNBC: Approved by the National Medical Products Administration (“NMPA”) for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies. The Company has initiated a Phase 3 registrational study of sac-TMT monotherapy versus investigator-choice chemotherapy for 1L advanced TNBC.

HR+/HER2- BC. In May 2025, the NDA for sac-TMT for the treatment of adult patients with unresectable locally advanced or metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting was accepted by the NMPA, and was included in the priority review and approval process. A Phase 3 registrational study of sac-TMT versus investigator’s choice of chemotherapy for treatment of patients with unresectable locally advanced, recurrent or metastatic HR+/HER2- BC who received prior endocrine therapy is in progress.

EGFR-mutant NSCLC. In March 2025, the Company received marketing authorization in China from the NMPA for sac-TMT for the treatment of adult patients with EGFR mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT monotherapy demonstrated a statistically significant and clinically meaningful improvement in ORR, PFS and OS compared with docetaxel. In addition, a Phase 3 registrational study of sac-TMT combined with osimertinib as first-line treatment of locally advanced or metastatic non-squamous EGFR-mutant NSCLC is in progress.

EGFR-wild type NSCLC. Two Phase 3 registrational studies of sac-TMT in combination with pembrolizumab are in progress. In June 2025, sac-TMT in combination with tagitanlimab was granted Breakthrough Therapy Designation by the NMPA for the first-line treatment of locally advanced or metastatic non-squamous NSCLC without actionable genomic alterations.

Other indications. The Company is actively exploring the potential of sac-TMT both as a monotherapy and in combination with other therapies for treating other solid tumors, including GC, EC, CC, OC, UC, CRPC and HNSCC.

Global clinical development. As of August 18, 2025, MSD is progressing 14 ongoing Phase 3 global, multi-center clinical studies for sac-TMT for several types of cancer including BC, LC, gynecological cancer and GI cancer. The Company is also collaborating with MSD on several global Phase 2 basket studies for sac-TMT as monotherapy or in combination with other agents for multiple solid tumors and those studies are ongoing.

Trastuzumab Botidotin (HER2 ADC, A166, 舒泰萊®[1])

In January 2025, an NDA for the treatment of adult patients with HER2+ unresectable or metastatic BC who have received at least one prior anti-HER2 therapy was accepted by the CDE of the NMPA.

Trastuzumab botidotin has met the primary endpoints of its pivotal Phase 2 trial for 3L+ and advanced HER2+ BC based on results from the primary analysis, and the NDA has been submitted to the NMPA.

The Company has initiated an open, multicenter Phase 2 clinical study of trastuzumab botidotin in the treatment of HER2+ unresectable or metastatic BC that previously received a topoisomerase 1 inhibitor ADC.

[1] The name of the product is subject to the approval of NMPA

Other ADC Products

SKB315 (CLDN18.2 ADC): the company is conducting a Phase 1b clinical trial of SKB315 and have initiated the exploration in combination with immunotherapy for the treatment of GC/GEJC. Results of a Phase 1 study of SKB315 will be presented at 2025 ESMO Congress in October 2025.

SKB410/MK-3120 (Nectin-4 ADC): has shown promising Phase 1 clinical data. MSD, as the partner, has launched the global Phase 1/2 clinical trial of SKB410.

SKB571/MK-2750: a novel bsADC that primarily targets various solid tumors such as LC and CRC etc. being developed in collaboration with MSD. The Phase 2 clinical trial in China is to be initiated.

SKB518, SKB535/MK-6204 and SKB445: novel ADC drugs with potential FIC targets. The Phase 2 clinical trial for SKB518 and the Phase 1 clinical trials for SKB535 and SKB445 are ongoing in China. The Company has entered into a license and collaboration agreement with MSD to develop SKB535.

SKB500 and SKB501: novel ADC drugs with verified targets but differentiated payload-linker strategies. The company been received a clinical trial notice approving the IND application of SKB501 and SKB500, respectively, for advanced solid tumors from the NMPA.

SKB107: a RDC drug jointly developed by the Company and the Affiliated Hospital of Southwest Medical University (西南醫科大學附屬醫院) targeting bone metastases in solid tumors. In March 2025, an IND application for SKB107 was approved by the NMPA and the Phase 1 study is ongoing.

Non-DC asset advancements are diversifying the innovation pipeline.

Tagitanlimab (PD-L1 mAb; A167; 科泰莱®):

The first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC.

We have received marketing authorization of tagitanlimab in China from NMPA for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy. In January 2025, we received marketing authorization of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic NPC in China from NMPA.

Cetuximab N01 (EGFR mAb; A140; 达泰莱®)

An EGFR mAb compared with Cetuximab Solution for Injection (Erbitux®)

In February 2025, we received marketing authorization in China from the NMPA for Cetuximab N01 Injection used in combination with FOLFOX or FOLFIRI regimens for first-line treatment of RAS wild-type mCRC.

A400/EP0031 (RET inhibitor): The Company is currently conducting pivotal clinical studies for 1L & 2L+ advanced RET+ NSCLC as well as a Phase 1b/2 clinical study for RET+ MTC and solid tumor in China. Through the Company’s collaboration and license agreement, Ellipses Pharma is progressing their phase 2 clinical study globally outside of China. 

SKB378/WIN378 (TSLP mAb): In January 2025, an IND application for SKB378 for the treatment of COPD was approved by the NMPA. The Company’s collaboration partner, Windward Bio, has launched the Phase 2 POLARIS trial in patients with asthma.

SKB336 (FXI/FXIa mAb): The Phase 1 clinical trial has been completed in China.

A296 (STING agonist): A Phase 1 trial is being carried out in China.

Commercialization Accelerates: Sales & Market Access Expanding Footprint

Sac- TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have been successively launched, marking the full-scale initiation of commercialization. The Company expects to launch trastuzumab botidotin (舒泰莱®) in the China market and file one NDA for A400 in the second half of 2025.

Sales performance: The total commercial sales reached RMB309.8 million for the first half of 2025. Among them, the sales of sac-TMT (佳泰莱®) accounted for 97.6%. At the same time, all accounts receivables from sales of pharmaceutical products were collected within the payment period, ensuring efficient and stable cash flow.

Market coverage and academic promotion: Currently, the company’s businesses have covered 30 provinces, over 300 prefectures, and over 2,000 hospitals, where over 1,000 hospitals generated sales, and reached tens of thousands of healthcare professionals through various types of marketing campaigns to convey product and medical professional information. In addition, the company has obtained authoritative endorsement for its products from experts in clinical guidelines, providing further support for the commercialization process. 

Commercialization system: The Company has established a fully-fledged marketing team of over 350 people, with a departmental structure that includes marketing, sales, medical affairs, strategic planning and commercial excellence, among other departments, as well as marketing compliance and KA functions. Through the efficient execution of the marketing team, the company has established relationships with multiple leading commercial and distribution groups, including 60+ Tier 1 distributors and 400+ DTP pharmacies. A hierarchical management system for pharmacy retail has been adopted and trainings have been provided to around 4,500 pharmacists in the first half of 2025. By organizing nationwide pharmacy trainings, the company has significantly enhanced the professionalism of terminal services and improved the ability to provide patients with medication guidance.

Market access: In the first half of 2025, sac-TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have been included in 29, 25 and 15 provincial networks, respectively, ensuring rapid market access through provincial procurement channels. Meanwhile, preparations for the National Reimburesement Drug List (國家醫保藥品目錄) access of marketed products are underway. Currently, sac-TMT (佳泰莱®), tagitanlimab (科泰莱®) and Cetuximab N01 (达泰莱®) have all passed the preliminary formal examination of National Reimbursement Drug List.

Meanwhile, to further reduce the burden of patients and implement the concept of inclusive healthcare, the company been proactively facilitating the enrollment of sac-TMT (佳泰莱®) in provincial and prefecture city level Inclusive Insurance (惠民保). As at the end of the Reporting Period, sac-TMT (佳泰莱®) has been enrolled in more than 7 provinces and 20 cities.

Global market: Globally, we will continue to pursue a flexible strategy to capture the commercial value in major international markets, through forging synergistic license and collaboration opportunities worldwide.

Global Collaboration Network Expansion & Authoritative Industry Recognition

In the first half of 2025, the Company continued to expand its global collaboration network and deepen partnerships. Working closely with collaborators, it is advancing clinical research worldwide with the goal of maximizing the global value of its pipeline, delivering high-quality medical solutions to patients, and strengthening its leading position in the biopharmaceutical sector.

Collaboration with MSD: As of the date of this announcement, MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as monotherapy or in combination with pembrolizumab or other agents, for several types of cancer including BC, LC, gynecological cancer and GI cancer.

In addition to sac-TMT, the Company is also collaborating with MSD on certain ADC assets including SKB410/MK-3120, SKB571/MK-2750, SKB535/MK-6204, etc. to continuously explore favorable ADC pipeline portfolios.

Collaboration with Ellipses Pharma: The Company has deepened its collaboration with Ellipses Pharma on A400/EP0031, which has been cleared by the FDA to progress into Phase 2 clinical development. As of June 30, 2025, Ellipses Pharma had set up a total of 36 clinical sites in the United States, Europe and UAE for EP0031.

Collaboration with Windward Bio: In January 2025, the Company and Harbour BioMed had entered into an exclusive license agreement with Windward Bio, under which the Company and Harbour BioMed granted Windward Bio an exclusive license for the research, development, manufacturing and commercialization of SKB378/WIN378 globally (excluding Greater China and several Southeast and West Asian countries).

In the first half of 2025, the Company earned high recognition from professional institutions and industry associations for its outstanding corporate management, product innovation, and strong performance in the capital market. In May 2025, the Company received “Asia’s Best Company” award from FinanceAsia (亞洲金融), as well as a series of awards from Extel, including “Most Honored Company”, “Best Company Board”, “Best CEO”, “Best CFO”, “Best ESG” and etc.. The Company was also awarded “IRM OF CHINESE LISTED COMPANIES” by Securities Times (證券時報). In July 2025, the Company was recognized with the “China Pharmaceutical Emerging Innovative Force Award” by the China National Pharmaceutical Industry Information Center (中國醫藥工業信息中心).

Additionally, the Company continues to strengthen its ESG strategy and improve its ESG governance structure to support sustainable development. The Company has established a comprehensive three-tier ESG governance structure consisting of the Board of Directors, ESG Working Group and ESG Executive Body. Through the establishment and continuous improvement of the ESG governance structure, the Company comprehensively enhances ESG performance ability.

Outlook

In the second half of 2025, the Company will continue to advance its differentiated pipelines targeting indications with significant medical needs, innovate and optimize payload-linker strategies, novel DC designs and structures, and expand application to non-oncology diseases. Meanwhile, the Company will further enhance its end-to-end drug development capabilities, advance towards commercialization and actively expand global footprints and strategic partnerships to maximize the value of its pipelines. In addition, the Company will continuously optimize its operation system to become a leading global biopharmaceutical company.

About Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (referred to as “Kelun-Biotech” Stock Code: 6990.HK) is a subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd., specializing in the R&D, production, commercialization, and international collaboration of innovative biotechnology and small-molecule drugs. The Company focuses on addressing unmet clinical needs both globally and in China, with a strategic emphasis on major disease areas such as oncology, autoimmune disorders, inflammation, and metabolic diseases. It is dedicated to building an international platform for drug R&D and industrialization, with the aim of becoming a global leader in the innovative drug sector. Currently, Kelun-Biotech has over 30 key innovative drug projects, including 3 projects that have received market approval, 1 project at the NDA stage, and more than 10 projects in clinical trials. The Company has also successfully established its internationally renowned proprietary ADC development platform, OptiDCTM, with 1 ADC project approved for market launch, 1 ADC project at the NDA stage, and several ADC or novel ADC projects in clinical or preclinical development. For more information, please visit the official website: https://kelun-biotech.com/

For further information, please contact:

Wonderful Sky Financial Group Ltd.
Angie Li & Jason Lai
Tel: (852) 6150 8598 / (852) 9798 0715
Email: po@wsfg.hk 

India’s leading healthcare network Manipal Hospitals welcomes India’s leading cancer specialist Dr. Surender Kumar Dabas to strengthen robotic cancer care in Delhi NCR

NEW DELHI, Aug. 18, 2025 /PRNewswire/ — Manipal Hospitals, one of India’s leading and globally recognized healthcare institutions, welcomes one of India’s most renowned robotic oncosurgeons, Dr. Surender Kumar Dabas as Chairman – Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster. With this addition, the hospital across Delhi, Gurugram and Ghaziabad further reinforces its vision to be a destination for world-class cancer care, catering to patients across India as well as international geographies.

Dr. Surender Kumar Dabas, Chairman - Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster
Dr. Surender Kumar Dabas, Chairman – Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster

Dr. Surender Dabas brings with him more than 22 years of experience in surgical oncology and has been a pioneer in the field of robotic head and neck cancer surgery. Over the years, he has performed over 30,000 cancer surgeries, including more than 4,000 robot-assisted procedures, making him one of the most experienced robotic oncosurgeons in India. His expertise spans robot-assisted surgeries for head and neck cancer, thoracic cancer, gynaecologic malignancies, urological cancer, gastrointestinal and colorectal cancer, and breast cancer.

Welcoming the doctor, Mr. Pramod Alagharu, Regional COO North-West Cluster, Manipal Hospitals, said, “We are proud to welcome Dr. Surender Dabas and his strong team of 150 medical experts. With his specialized expertise in managing complex cancer procedures, Dr. Dabas brings immense value to our commitment to delivering world-class healthcare, including robot-assisted cancer treatment. His leadership will strengthen our role as a preferred destination for complex oncology cases for both domestic and international patients.

Speaking about his new role, Dr. Surender Kumar Dabas, Chairman Manipal Comprehensive Cancer Centre and Onco Robotic Surgeries, North-West Cluster added, “I am excited to join the Manipal family, one of the largest healthcare networks in India, which has a long-standing reputation for excellence in healthcare. My goal is to build on a strong foundation here and bring the most advanced and precise cancer care to both national and international patients. Through the use of robotics and newer technologies, we aim to make surgeries safer, less invasive, and more effective, improving both survival and quality of life for our patients.”

With Dr. Dabas leading the Manipal Comprehensive Cancer Centre, the hospital is poised to emerge as a centre of excellence in comprehensive cancer care, offering advanced clinical protocols, evidence-based treatment, and a multidisciplinary approach to managing cancer. This will further position Manipal Hospitals as a trusted partner for international patients seeking high-quality, technology-led cancer treatment in India.

For any inquiries, contact our team at query.mhd@manipalhospitals.com or call us +91 8527388881.

About Manipal Hospitals

As a pioneer in healthcare, Manipal Hospitals is among the top healthcare providers in India serving over 7 million patients annually. Its focus is to develop an affordable, high-quality healthcare framework through its multispecialty and tertiary care delivery spectrum and further extend it to out-of-hospital care. With the completion of the acquisition of Medica Synergie hospitals and AMRI Hospitals Limited (acquired in Sept 2023), the integrated network today has a pan-India footprint of 38 hospitals across 19 cities with 10,500+ beds and a talented pool of 7,200+ doctors and an employee strength of over 20,500.

Manipal Hospitals provides comprehensive curative and preventive care for a multitude of patients from around the globe. Manipal Hospitals is NABH and AAHRPP accredited, and most of the hospitals in its network are NABL, ER, and Blood Bank accredited and recognized for Nursing Excellence. Manipal Hospitals has also been recognized as the most respected and patient-recommended hospital in India through various consumer surveys.